









Markets
/
Stocks
/
nasdaq-pvla
/

Palvella Therapeutics Inc

PVLA

59.040USD

+2.470+4.37%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

652.96MMarket Cap

LossP/E TTM



Palvella Therapeutics Inc

59.040

+2.470+4.37%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-18

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

81 / 506

Overall Ranking

185 / 4721

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 13 analysts

Buy

Current Rating

65.461

Target Price

+15.72%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Palvella Therapeutics, Inc., formerly Pieris Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases. Its lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is in the Phase III SELVA clinical trial in microcystic lymphatic malformations (microcystic LMs) and a Phase II trial in cutaneous venous malformations. It is also engaged in developing treatment for other serious, functionally debilitating skin diseases driven by the overactivation of the mammalian target of rapamycin (mTOR) pathway.

Undervalued

The company’s latest PE is -10.89, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 8.02M shares, increasing 15.52% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 163.81K shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-18

The company's current financial score is 6.80, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.80

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.24

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.98

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-18

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -10.43, which is -91.42% below the recent high of -0.89 and 78.54% above the recent low of -2.24.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 81/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-18

The company’s current earnings forecast score is 8.31, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Palvella Therapeutics Inc is 62.00, with a high of 90.00 and a low of 49.99.

Score

Industry at a Glance

Previous score

8.31

Change

Support & Resistance

No Data

Analyst Rating

Based on 13 analysts

Buy

Current Rating

65.461

Target Price

+15.72%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Palvella Therapeutics Inc

PVLA

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-18

The company’s current price momentum score is 6.82, which is higher than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 63.34 and the support level at 47.94, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.82

Change

-0.01

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

-0.970

Neutral

RSI(14)

65.613

Neutral

STOCH(KDJ)(9,3,3)

57.364

Buy

ATR(14)

3.920

Low Volatility

CCI(14)

122.969

Buy

Williams %R

20.923

Buy

TRIX(12,20)

1.082

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

56.318

Buy

MA10

56.718

Buy

MA20

54.903

Buy

MA50

44.661

Buy

MA100

34.046

Buy

MA200

26.510

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-18

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 72.53%, representing a quarter-over-quarter increase of 10.71%. The largest institutional shareholder is The Vanguard, holding a total of 163.81K shares, representing 1.48% of shares outstanding, with 1337.96% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Kaupinen (Wesley H.)

1.61M

Frazier Life Sciences Management, L.P.

690.01K

+5.52%

Suvretta Capital Management, LLC

714.46K

BVF Partners L.P.

696.55K

Integrated Finance Group

559.95K

Woodline Partners LP

194.17K

BlackRock Institutional Trust Company, N.A.

110.75K

+758.34%

Samsara BioCapital, LLC

679.49K

Millennium Management LLC

269.84K

Adams Street Partners, LLC

409.67K

Risk Assessment

Currency: USD Updated: 2025-09-18

The company’s current risk assessment score is 5.10, which is higher than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is -0.15. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.